The issuance of a U.S. patent for Trappsol Cyclo represents a significant milestone for Cyclo Therapeutics in its efforts to develop treatments for Alzheimer's disease. This patent not only strengthens the company's intellectual property portfolio but also enhances its position in the biotechnology market, particularly in the Alzheimer's treatment space. The news is likely to be viewed positively by investors, as it demonstrates progress in the company's research and development efforts and potential for future revenue through the commercialization of Trappsol Cyclo.